Date: 2013-06-13
Type of information:
phase: 1-2
Announcement: authorization of the trial
Company: apceth (Germany)
Product: Agenmestencel-T (genetically modified, adult mesenchymal stem cells)
Action mechanism: This therapy is based on mesenchymal stem cells harvested from the patient\'s own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient. The stem cells thus modified specifically target the tumor and the cytotoxic gene product is selectively activated at the site of the tumor or its metastases to increase local efficacy and to reduce systemic toxicity, one of the main problems of systemic chemotherapy. This unique principle is also applicable to other cancer types.
Disease: advanced adenocarcinomas of the gastrointestinal tract
Therapeutic area: Cancer - Oncology
Country: Germany
Trial
details: The multicenter, open-label trial will recruit patients suffering from advanced adenocarcinomas of the gastrointestinal tract. This clinical trial will be initiated at the University Hospital Grosshadern in Munich in collaboration with experts from the National Center of Tumor Diseases (NCT) in Heidelberg and the Karolinska Institute in Stockholm.
Latest
news: * On June 13, 2013, apceth has received approval to conduct a clinical cancer trial with its genetically modified, adult mesenchymal stem cells. The multicenter, open-label trial will recruit patients suffering from advanced adenocarcinomas of the gastrointestinal tract. The trial will be initiated in the next few weeks. While apceth is already being supported by numerous national and international grants, the company has just concluded another round of financing of € 22 m from their existing investors. This will enable apceth to further develop its innovative cellular therapeutics right up to the clinical testing stage.
